Retinitis clinical trials
The registry lists 47 studies for Retinitis across more than 10 countries. 1 are recruiting or about to start. 1 of them are mainly about Retinitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-07-01. Counting its narrower condition Cytomegalovirus Retinitis too: 75 studies, 2 open.
Get an email when these change. Save the Retinitis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Allergy and Infectious Diseases (NIAID) (15) · Hoffmann-La Roche (6) · Astra USA (4) · Roche Global Development (3) · Nanoscope Therapeutics Inc. (2) · National Eye Institute (NEI) (2) · Gilead Sciences (2) · ProQR Therapeutics (1)
What is being tested here
Drugs under test in Retinitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ganciclovir | 0 | 3 | 19 |
| Foscarnet | 0 | 0 | 9 |
| Cidofovir | 0 | 0 | 3 |
| Zidovudine | 0 | 0 | 1 |
| Acyclovir | 0 | 0 | 1 |
| Sevirumab | 0 | 0 | 1 |
| Aldesleukin | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
Who these studies take
Of the 1 Retinitis studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 0 (0%) | 0 (0%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 47 studies, recruiting or not: 32% stop at 75 or younger and 32% at 65; 64% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 47 of 47. search them.
- Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.RecruitingNCT07679412Not applicable1 country
- Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE StudyActive, not recruitingNCT061625852 countries
- Natural History Study of Retinitis Pigmentosa Type 11Active, not recruitingNCT048056581 country
- Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]CompletedNCT04945772Phase 22 countries
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of CareCompletedNCT014313265 countries
- A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO GeneActive, not recruitingNCT04123626Phase 1/21 country
- Ocular Manifestations in Rheumatic DiseasesCompletedNCT03753893
- A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Cannot Use GanciclovirWithdrawnNCT00000697Phase 2
- The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVCompletedNCT00001034Phase 21 country
- A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With GanciclovirCompletedNCT00000970Phase 11 country
- The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDSCompletedNCT00000989Not applicable1 country
- A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment FailureCompletedNCT00000691Phase 21 country
- Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency SyndromeCompletedNCT00000726Phase 11 country
- A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral GanciclovirCompletedNCT00000668Phase 11 country
- Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDSCompletedNCT00000693Not applicable1 country
- A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic TherapyCompletedNCT00000673Phase 11 country
- The Effects of Genetic Differences Among AIDS Patients on Cytomegalovirus RetinitisCompletedNCT003411721 country
- Exercise and RP (AVAMC and Emory)CompletedNCT03381235Not applicable1 country
- Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind PatientsCompletedNCT01024803Not applicable3 countries
- Screening for NEI Clinical StudiesCompletedNCT000017341 country
- Stem Cell Transplantation in Ocular Lesions of Behcet's DiseaseTerminatedNCT00550498Phase 11 country
- The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDSCompletedNCT00000981Phase 21 country
- HPMPC (Cidofovir) Peripheral CMV Retinitis Trial ProtocolCompletedNCT00000799Not applicable1 country
- Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir ComponentCompletedNCT00000665Not applicable1 country
- A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDSCompletedNCT00000688Phase 31 country
- CMV Retinitis Retreatment TrialCompletedNCT00000766Phase 21 country
- A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV RetinitisCompletedNCT00000698Phase 31 country
- Immune Activity Against CVM RetinitisCompletedNCT000016111 country
- A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDSCompletedNCT00002257Not applicable2 countries
- A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)CompletedNCT00002125Phase 41 country
- Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised PatientCompletedNCT00002025Not applicable1 country
- An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous AccessCompletedNCT00002135Not applicable1 country
- An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS PatientsCompletedNCT00002039Not applicable1 country
- A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDSCompletedNCT00002034Not applicable2 countries
- A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV RetinitisCompletedNCT00002016Phase 11 country
- A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus RetinitisCompletedNCT00002134Not applicable1 country
- Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV RetinitisCompletedNCT00002070Phase 31 country
- An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDSCompletedNCT00002142Not applicable1 country
- A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDSCompletedNCT00001999Not applicable1 country
- A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCompletedNCT00002432Not applicable1 country
- The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCompletedNCT00002299Not applicable1 country
- An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in ChildrenCompletedNCT00002015Not applicable1 country
- The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCompletedNCT00002437Phase 22 countries
- A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) RetinitisCompletedNCT00002321Phase 11 country
- A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir TherapyCompletedNCT00002247Not applicable2 countries
- A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With GanciclovirStatus unknownNCT00002301Not applicable1 country
- A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCompletedNCT00002330Not applicable2 countries